Asymchem Laboratories Tianjin Starts API Workshop Operation
This article was originally published in PharmAsia News
Asymchem Laboratories (Tianjin), China's leading pharmaceutical R&D outsourcing company, recently started operating its active pharmaceutical ingredient workshop in the Tianjin Economic-Technological Development Area. With two independent production lines (50L and 100L), the facility can process raw pharmaceutical materials to produce tablets and capsules with APIs. In addition, it is also capable of small-scale R&D and oral solution output. The latest move will expand the firm's capability in high-efficiency compound R&D and production. (Click here for more - Chinese Language)
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.